Jean De VryThomas M TzschentkeElsevier Ireland LtdNeuroscience LettersChristoph T, De Vry J. and Tzschentke TM (2010) Tapentadol, but not morphine, selectively inhibits disease- related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neurosci Lett 470:91-94....
Tapentadol glucuronide was the main metabolite in the plasma/serum (79–84 % of total plasma/serum exposure (AUC)), followed by tapentadol catechol-glucuronide (4–10 %) and N-demethyl-tapentadol glucuronide (4–9 %). Tapentadol sulphate was also found in the dog plasma (3%) and human ...
Blood samples were collected immediately after the pharmacodynamic measurements of tramadol to determine pharmacokinetics and the active metabolite O-demethyltramadol (M1).ResultsTapentadol and morphine induced dose-dependent antinociception with ED50-values of 4.3mgkg1 and 0.71mgkg1, respectively. In ...
Christoph T, Meen M, de Vry J, Tzschentke TM. Efficacy of tapentadol, a novel centrally acting analgesic with dual mode of action, in animal models of chronic neuropathic pain. Eur J Pain 2007;11(Suppl. 1):61.Christoph T, Méen M, De Vry J, Tzschentke TM (2007) Efficacy of ...
J. De VryElsevier Inc.Journal of PainTzschentke TM. Poster 227: efficacy profile of tapentadol, a novel centrally acting analgesic with a combined mode of action, in animal pain models. 27th American Pain Society Annual meeting; 2008.